Executive summary
Updated 4 November 2026
© Crown copyright 2026
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/178th-acnfp-meeting-16-and-17-september-2026/executive-summary
-
Dry biomass of Paecilomyces variotii KCL-24 RP2305- The Committee reviewed this novel food application for dry biomass of Paecilomyces variotii KCL-24 for the first time. Information gaps to meet the requirements of the novel foods technical guidance were identified in the identity, production process, composition, specification, proposed uses, ADME, nutritional information and toxicology sections. The Secretariat was advised to seek further information from the applicant to support further review of this dossier at the next available meeting.
-
Beta-lactoglobulin RP1571- The Committee reviewed this novel food application for beta-lactoglobulin for the fourth time and concluded the risk assessment. The Committee provided feedback and this input will be incorporated into the Committee Advice Document ahead of publication.
-
CBD- Group C RP450- The Committee reviewed this novel food application for Cannabis sativa extract for the second time. Information gaps to meet the requirements of the novel foods technical guidance were identified in the identity, production process, composition, specification, ADME and toxicology sections. The Secretariat was advised to seek further information from the applicant to support further review of this dossier at the next available meeting.
-
Workshop to explore factors that influence setting a safe use level for novel protein sources- The Committee considered factors influencing the establishment of safe use levels for novel protein sources and noted that confidence in the margin of safety is dependent on the quality of compositional, protein characterisation and toxicological data. Further consideration to continue at the next available meeting.
-
Cell-cultivated duck RP2241– The Committee reviewed this CCP application for the fourth time. The Committee completed a detailed hazard review of the novel food, considering all information provided by the applicant and reviewed an updated Committee Advice Document identifying information gaps. The Secretariat was advised to update the Committee Advice Document once the applicant responses on the intake and exposure assessments are received, to support further review at the next available meeting.
-
Mosa Meat B.V- Cell-cultured bovine fat biomass RP2307- The Committee reviewed this CCP application for the first time. The Committee reviewed the Committee Advice Document and identified clarification was required in several areas of the assessment before any further comments could be made. The Secretariat was advised to seek further information from the applicant to support further review of this dossier at the next available meeting.